Analysis of IgG reactivity against human papillomavirus type-16 E7 in patients with cervical intraepithelial neoplasm indicates an association with clearance of viral infection: results of a prospective study
Open Access
- 6 December 1996
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 68 (6) , 731-738
- https://doi.org/10.1002/(sici)1097-0215(19961211)68:6<731::aid-ijc7>3.0.co;2-4
Abstract
IgG reactivity against the immunodominant region aa6‐35 of Human Papillomavirus (HPV) type‐16 E7 was determined in a peptide‐based ELISA in a cohort study of women with initial mild to moderate cervical dyskaryosis. On the basis of HPV DNA patterns, as determined by PCR in cervical smears prior to IgG testing, HPV‐16‐positive patients were grouped as having either a cleared, a fluctuating, or a persistent HPV‐16 infection. In a cross‐sectional study at the start of serological follow‐up, positive IgG reactivities were found more often in the total group of HPV‐16‐positive patients (20.0%) than in patients consistently typed as HPV‐negative over a period of at least 12 months prior to testing (3.1%, p < 0.04). The highest proportion of positive responders was found in patients with a cleared HPV‐16 infection (29.4%). Also, IgG reactivities found in HPV‐16 clearance patients were significantly higher than in patients with a persistent infection (p < 0.008). In a subsequent longitudinal study over a period of up to 27 months, consistently positive reactivities were observed in patients with cleared viral infections who showed seroreactivity in the cross‐sectional study, while mostly negative reactivities were found in patients with viral persistence. HPV‐16 E7‐specific IgG subclass responses were determined in a selection of 19 CIN and 11 HPV‐ 16‐positive cervical carcinoma (CeCa) patients with positive E7‐specific IgG responses. IgG2 was predominant in the CIN patients, suggesting the presence of IFNγ (Th1) at the site of HPV infection. In the CeCa patients IgG1 and IgG2 were produced equally, possibly indicating a rise in Th2 cytokines. Our data suggest that HPV‐16 E7 IgG reactivity in a subset of CIN patients with viral clearance may result from successful Th1 responses. © 1996 Wiley‐Liss, Inc.Keywords
This publication has 18 references indexed in Scilit:
- T Cell Proliferative Responses Against Human Papillomavirus Type 16 E7 Oncoprotein are Most Prominent in Cervical Intraepithelial Neoplasia Patients with a Persistent Viral InfectionJournal of General Virology, 1996
- Follow‐up of antibody responses to human papillomavirus type 16 E7 in patients treated for cervical carcinomaJournal of Medical Virology, 1995
- IgG2 Deficiency Associated with Defects in Production of Interferon‐Gamma; Comparison with Common Variable ImmunodeficiencyScandinavian Journal of Immunology, 1995
- Antibodies to the E4, E6, and E7 Proteins of Human Papillomavirus (HPV) Type 16 in Patients with HPV-Associated Diseases and in the Normal PopulationJournal of Investigative Dermatology, 1995
- Presence Of Antibodies To Seven Human Papillomavirus Type 16-DerivedThe Journal of Infectious Diseases, 1994
- Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patientsArchiv für die gesamte Virusforschung, 1994
- Role of interleukin-4 in human immunoglobulin E formation in hu-PBL-SCID mice.Journal of Clinical Investigation, 1994
- Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3.The Journal of Experimental Medicine, 1994
- Serologic response in human papillomavirus‐associated invasive cervical cancerInternational Journal of Cancer, 1993
- Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISAJournal of General Virology, 1990